Clinical Trial Update: An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy [Phase 2]

View source ↗

Summary

An open-label Phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of CB03-154 in subjects with focal epilepsy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Epilepsy

Drugs mentioned

• CB03-154

Snippet

Sponsor: Shanghai Zhimeng Biopharma, Inc. | Conditions: Focal Epilepsy | Phase 2 | Status: RECRUITING